Physician profile
Bett Eng
NPI 1861408742
$11,678.76
in general payments reported to CMS, 2019-2025
22 companies · $965 in 2025
The $965 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,592 · 2021: $1,915 · 2022: $1,945 · 2023: $2,068 · 2024: $1,347 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,277.97 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $2,185.65 | 2019-2025 | |
| Janssen Biotech, INC. | $1,993.22 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,193.00 | 2019-2025 | |
| Pfizer INC. | $939.36 | 2019-2023 | |
| Aurinia Pharma U.S., INC. | $315.13 | 2021-2023 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $304.55 | 2019-2023 | Orencia |
| Lilly USA, LLC | $300.22 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $294.72 | 2019-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $274.53 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $254.69 | 2019-2021 | |
| Horizon Therapeutics Plc | $245.02 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $229.34 | 2023-2025 | Idacio |
| Celgene Corporation | $221.37 | 2019 | |
| Ucb, INC. | $183.65 | 2019-2024 | Cimzia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $140.43 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $100.75 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $85.21 | 2021-2023 | |
| Radius Health, INC. | $50.67 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $39.97 | 2020 | |
| Mallinckrodt Hospital Products INC. | $26.68 | 2023 | Acthar |
| Scilex Pharmaceuticals INC. | $22.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bett Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.